Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Many dosing-related statements appear broadly consistent with on-label concepts (individualization/titration, maintenance dosing, and adjustment for tolerability/response), but the provided label excerpts do not substantiate several specific claims (titration step details, enzyme-inhibitor interaction dosing reductions, and clinicial avoidance of combinations). Indication-related claims for AUSTEDO XR (tardive dyskinesia and Huntington’s disease chorea) are not supported or contradicted by the supplied excerpts, limiting verification.
Category Scores
Accurate Statements
Austedo XR is used for tardive dyskinesia.
Not supported or contradicted by the provided label excerpts.
Austedo XR is used for chorea associated with Huntington’s disease.
Not supported or contradicted by the provided label excerpts.
Co-medications affect Austedo XR titration.
Not supported by the provided excerpts.
Deutetrabenazine exposure can change when taken with certain strong or moderate inhibitors of drug-metabolizing enzymes.
Unsupported Statements
Clinicians increase Austedo XR gradually to reach a recommended maintenance dose range.
The provided excerpts include suicidality/depression content only; no dosing/titration schedule or maintenance range details are provided.
Austedo XR dosing is titrated based on the condition being treated.
No indication-specific titration details are provided in the excerpts.
Austedo XR dosing is titrated based on how a patient responds.
No label excerpt provided addressing response-based titration.
Clinicians start Austedo XR at a low dose for most patients.
No starting-dose information is provided in the excerpts.
Austedo XR dosing is adjusted for tolerability.
No tolerability-based dose adjustment guidance is provided in the excerpts.
Exact titration steps for Austedo XR depend on the indication.
No titration step-by-step guidance is provided in the excerpts.
Exact titration steps for Austedo XR depend on patient factors.
No titration step-by-step guidance is provided in the excerpts.
Tolerability affects Austedo XR titration.
No label excerpt provided addressing tolerability in titration.
Co-medications affect Austedo XR titration.
No interaction/titration guidance is provided in the excerpts.
The maintenance dose range and target dose for Austedo XR are determined by the prescribing regimen.
No maintenance/target dose range details are provided in the excerpts.
The maintenance dose range and target dose for Austedo XR are determined by patient response.
No maintenance/target dose range details are provided in the excerpts.
Clinicians may reduce Austedo XR dosing when taken with certain strong or moderate enzyme inhibitors.
Although one claim references exposure changes, the provided excerpts do not include enzyme-inhibitor interaction dosing-reduction instructions.
Clinicians may avoid specific combinations to limit the risk of adverse effects.
No combination-avoidance guidance or interaction contraindication/avoidance language is included in the provided excerpts.
Austedo XR is an extended-release tablet.
This is consistent with the provided product identification, but no excerpted label text for dosage form is included in the prompt’s label sections.
Austedo XR dosing is individualized.
No dosing individualization language is provided in the excerpts.
Austedo XR dosing differs by the neurologic condition being treated.
No dosing-by-indication guidance is provided in the excerpts.
Contradictions
Important Omissions
No label excerpt was provided to verify contraindications, warnings/precautions (beyond depression/suicidality), drug-drug interaction specifics, adverse reactions, monitoring outside suicidality/depression, or administration/storage instructions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several specific dosing/titration and interaction-management statements are not supported by the supplied label excerpts. While the suicidality/depression warning is well-aligned with the provided sections, unsupported dosing/interaction claims could misrepresent clinician actions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Most dosing titration and interaction-management claims are not supported by the excerpted FDA label sections provided (which focus on depression/suicidality).
Suggested Improvement
Limit claims to information explicitly present in the provided label excerpts (e.g., depression/suicidality risk, contraindications for suicidal/untreated depression in Huntington’s disease, and monitoring/medication-guide counseling). For dosing and enzyme-inhibitor interaction specifics, cite the relevant sections from the prescribing information.